87943-97-3

Usage

Uses

Used in Pharmaceutical Industry:
ETHYL 2-BROMO-3-(4-BROMOPHENYL)-3-OXO-PROPANOATE is used as a building block for the synthesis of pharmaceutical compounds. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical industry, ETHYL 2-BROMO-3-(4-BROMOPHENYL)-3-OXO-PROPANOATE is used as a precursor for the production of agrochemicals, such as pesticides and herbicides, due to its reactive functional groups and potential for further chemical modification.
Used as an Intermediate in Chemical Synthesis:
ETHYL 2-BROMO-3-(4-BROMOPHENYL)-3-OXO-PROPANOATE serves as an intermediate in the synthesis of other chemicals, contributing to the development of novel compounds with various applications.
Used in Research and Development:
ETHYL 2-BROMO-3-(4-BROMOPHENYL)-3-OXO-PROPANOATE is also utilized in research and development settings, where its unique properties can be explored for new applications and to enhance existing chemical processes.

Upstream product

• 26510-95-2 ethyl 4-Bromobenzoylacetate 
• 99-90-1 para-bromoacetophenone 

Downstream Products

• 87944-10-3 ethyl 4-(4-bromophenyl)-2-dimethylaminothiazole-5-carboxylate 
• 1007884-76-5 (2S)-2-(1-(4-bromophenyl)-3-ethoxy-1,3-dioxopropan-2-yl) 1-tert-butyl pyrrolidine-1,2-dicarboxylate 
• 1319191-58-6 C₁₉H₂₄BrNO₇ 
• 1073467-90-9 3,6-bis(4-bromophenyl)-1H,4H-furo[3,4-c]furan-1,4-dione 
• 1423705-67-2 C₁₂H₁₀BrNO₃ 
• 834885-05-1 ethyl 2-amino-4-(4-bromophenyl)thiazole-5-carboxylate 
• 1423705-69-4 C₁₈H₁₅BrN₂O₃ 
• 1368558-04-6 C₁₀H₆BrNO₃ 
• 1423692-01-6 C₂₈H₂₃N₂O₄S^(1-)*Na⁽¹⁺⁾ 

Relevant academic research and scientific papers

Highly efficient and green synthesis of 2,4-diphenyl substituted thiazoles

2,4-Diphenyl thiazole is an important organic intermediate and its derivatives contain multiple biological properties. In the present study, we reported a new protocol to synthesize 2,4-diphenyl thiazole analogs, which involved the bromination of ethyl benzoylacetates with NBS in the presence of 2-hydroxypropyl-β-cyclodextrin, followed by a direct cyclization with thiobenzamides in water. Compared with the reported method, the current protocol contains less reaction steps, milder reaction conditions, and simpler workup procedure.

Highly Luminescent Encapsulated Narrow Bandgap Polymers Based on Diketopyrrolopyrrole

We present the synthesis and characterization of a series of encapsulated diketopyrrolopyrrole red-emitting conjugated polymers. The novel materials display extremely high fluorescence quantum yields in both solution (>70%) and thin film (>20%). Both the absorption and emission spectra show clearer, more defined features compared to their naked counterparts demonstrating the suppression of inter and intramolecular aggregation. We find that the encapsulation results in decreased energetic disorder and a dramatic increase in backbone colinearity as evidenced by scanning tunnelling microscopy. This study paves the way for diketopyrrolopyrrole to be used in emissive solid state applications and demonstrates a novel method to reduce structural disorder in conjugated polymers.

Expanding Blaise-Type Reactions towards Indium-Mediated Transformations of α-Bromo-β-keto Esters with Nitriles

The aim of this work is the identification of mild reaction conditions for the Blaise-type transformation of brominated β-keto esters with nitriles to generate enamino-substituted keto esters. The best results were obtained when a combination of indium metal (0.7 equiv.) with indium trichloride (1.6 equiv.) were applied at 60 °C for 20 to 72 hours, and these conditions could be applied to a broad range of nitriles and a significant number of different β-keto esters. The transformation of aliphatic nitriles proved to be difficult and gave only moderate yields. However, aromatic nitriles gave good yields in many cases. The applicability range of β-keto esters is acceptable while some electron-deficient aryl-substituents on the keto ester were challenging substrates. Nevertheless, we were able to expand the scope of the Blaise-type reaction towards brominated β-keto esters significantly.

Hepatitis C virus inhibitors

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: [in-line-formulae]Q-G-A-L-B—Z—W??(I),[/in-line-formulae] which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Preparation method for 2-halogenated-1,3-dicarbonyl derivative

The invention discloses a preparation method for a 2-halogenated-1,3-dicarbonyl derivative. The preparation method is suitable for wide 1,3-dicarbonyl derivatives. The raw materials are easy to obtain, and multiple varieties are achieved. The product obtained through the method is diversified in type, and can be directly used and used for other further reactions. According to the method, reaction conditions are gentle, the reaction operation and after-treatment process is simple, reaction time is short, the yield is high, pollution is low, and the preparation method is suitable for industrial production.

HEPATITIS C VIRUS INHIBITORS

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: (structurally represented), which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

HEPATITIS C VIRUS INHIBITORS

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: Q-G-A-L-B-Z-W (I) which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

HEPATITIS C VIRUS INHIBITORS

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: Q-G-A-L-B-W (I) which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the

Cross-linked polymers based on 2,3,5,6-tetra-substituted pyrrolo[3,4-c]pyrrole-1,4(2H,5H)-dione (DPP): Synthesis, optical and electronic properties

A series of 2,3,5,6-tetra-substituted pyrrolo[3,4-c]pyrrole-1,4(2H,5H)-dione (DPP) derivatives carrying thienyl-, 3,4-ethylenedioxy-thienyl- (EDOT-) and 3,4-ethylenedithiathienyl- (EDTT-) substituent groups have been synthesized and electrochemically poly

Hepatitis C Virus Inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.